Arcadia Biosciences
RKDA
15 hedge funds and large institutions have $1.21M invested in Arcadia Biosciences in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 17 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
89% more capital invested
Capital invested by funds: $640K → $1.21M (+$570K)
25.87% more ownership
Funds ownership: 0.24% → 26.11% (+26%)
46% less funds holding
Funds holding: 28 → 15 (-13)
76% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$733K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$561K |
| 3 |
State Street
Boston,
Massachusetts
|
+$102K |
| 4 |
Millennium Management
New York
|
+$59K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$83.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$76.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$49.2K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$48K |
| 5 |
Renaissance Technologies
New York
|
-$39K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
26
Virtu Financial
New York
| – | -$4K | -328 | Closed |
|
|
CA
27
Calton & Associates
Tampa,
Florida
| – | -$3.52K | -325 | Closed |
|
28
Goldman Sachs
New York
| – | -$2.99K | -276 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$2.83K | -267 | -99% |
|
30
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$54 | -5 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$32 | +3 | +300% |
|
RKDA Hedge Fund Activity: Q1 2023 in Review
15 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q1 2023, worth a combined $1.21M — up 89% from $640K a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RKDA and 4 opened new positions — a net loss of 13 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Armistice Capital, adding an estimated $733K. The largest seller was Vanguard Group, exiting entirely with an estimated $83.3K sold.
- 15 institutional investors held Arcadia Biosciences (RKDA) as of Q1 2023, down from 28 in Q4 2022.
- Funds reported $1.21M of Arcadia Biosciences stock for Q1 2023, up 89% quarter-over-quarter.
- 4 funds opened new Arcadia Biosciences positions in Q1 2023 and 17 closed out, a net change of -13 holders.
- The largest Arcadia Biosciences buyer in Q1 2023 was Armistice Capital, an estimated $733K added.
- The largest Arcadia Biosciences seller in Q1 2023 was Vanguard Group, an estimated $83.3K sold.
Based on aggregated 13F filings for Q1 2023.